Celina Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celina Liu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Surapaneni
Division of Precision Medicine, Department of Medicine New York University Grossman School of Medicine New York NY USA
1 shared publication - Alix Rosenberg
Zucker School of Medicine, Hofstra University Uniondale New York USA
1 shared publication - Amanda Hyre Anderson
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana
1 shared publication - Avantika Israni
Nephrology Division, Department of Medicine, NYU Grossman School of Medicine, New York, New York
1 shared publication - Brian Lynch
Department of Orthopaedic Surgery, Stony Brook University Hospital, Stony Brook, New York
1 shared publication - Bronya L. Sandorffy
Nephrology Division, Department of Medicine, NYU Grossman School of Medicine, New York, New York
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (2)
Longitudinal Trends in Female Representation Among Orthopaedic Residency Programs Most Visible to Potential Applicants, 2005 to 2025
Background: Despite comprising 50.5% of medical students, women remain underrepresented in orthopaedic surgery. As of 2024, orthopaedics had the lowest rate of female residents among surgical specialties at 23.7%. While early exposure programs and signaling have helped promote access, some residencies still match classes without a female resident. Tracking long-term trends in female match rates may highlight opportunities to improve representation. The purpose of this study was to provide longitudinal context for the gender composition of orthopaedic residency programs most visible to applicants by tracking changes in female representation from 2005 to 2025. Methods: We used Doximity’s Residency Navigator to sort programs by perceived reputation, and the programs in the top third results were included in our analysis as these programs are most visible to residency applicants and are presumed to shape applicant perceptions and behavior. Gender composition of interns was collected from program websites and social media for each available year. Weighted linear regression assessed temporal trends; two-proportion Z-tests evaluated regional and urbanicity differences. Results: Among 69 programs, women comprised 23.2% of interns overall. Representation rarely exceeded 20% before 2017, reaching a low of 11.5% in 2006, but surpassed 30% annually since 2022. Female representation increased by 1.2% per year (p < 0.001, R 2 = 0.77). Regional variation persisted, but growth was consistent across geography and program size. Significant increases occurred in metropolitan programs (+18.9%, p < 0.0001) from 2015 to 2025. Conclusion: Female representation at orthopaedic programs most visible on Doximity has risen steadily, with a marked inflection after 2017 and exceeding 30% since 2022. These gains likely reflect combined effects of diversity initiatives, preference signaling, and broader cultural movements advocating gender equity. Future research should examine the impact of signaling on gender diversity and evaluate gender diversity in all orthopaedic residency programs.
- 1 April 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (2)
Open AccessLongitudinal Trends in Female Representation Among Orthopaedic Residency Programs Most Visible to Potential Applicants, 2005 to 2025
Background: Despite comprising 50.5% of medical students, women remain underrepresented in orthopaedic surgery. As of 2024, orthopaedics had the lowest rate of female residents among surgical specialties at 23.7%. While early exposure programs and signaling have helped promote access, some residencies still match classes without a female resident. Tracking long-term trends in female match rates may highlight opportunities to improve representation. The purpose of this study was to provide longitudinal context for the gender composition of orthopaedic residency programs most visible to applicants by tracking changes in female representation from 2005 to 2025. Methods: We used Doximity’s Residency Navigator to sort programs by perceived reputation, and the programs in the top third results were included in our analysis as these programs are most visible to residency applicants and are presumed to shape applicant perceptions and behavior. Gender composition of interns was collected from program websites and social media for each available year. Weighted linear regression assessed temporal trends; two-proportion Z-tests evaluated regional and urbanicity differences. Results: Among 69 programs, women comprised 23.2% of interns overall. Representation rarely exceeded 20% before 2017, reaching a low of 11.5% in 2006, but surpassed 30% annually since 2022. Female representation increased by 1.2% per year (p < 0.001, R 2 = 0.77). Regional variation persisted, but growth was consistent across geography and program size. Significant increases occurred in metropolitan programs (+18.9%, p < 0.0001) from 2015 to 2025. Conclusion: Female representation at orthopaedic programs most visible on Doximity has risen steadily, with a marked inflection after 2017 and exceeding 30% since 2022. These gains likely reflect combined effects of diversity initiatives, preference signaling, and broader cultural movements advocating gender equity. Future research should examine the impact of signaling on gender diversity and evaluate gender diversity in all orthopaedic residency programs.
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 801-813
Class 1 Indications for Coronary Revascularization Identified in Prekidney Transplant Screening
Key Points: Coronary artery disease is a barrier to kidney transplantation. Many transplant programs mandate routine coronary artery disease screening. It remains unclear how many patients meet class 1 indication for revascularization. We conducted a meta-analysis to estimate the prevalence. Despite high frequency of screening, we found a relatively low prevalence of class 1 indication for coronary revascularization. Background: Cardiovascular disease is the most common cause of morbidity and mortality in kidney transplant recipients. Screening for coronary disease is frequently required before kidney transplantation, but coronary intervention has not been shown to be beneficial except in complex coronary artery disease. The likelihood of finding significant coronary artery disease and the benefits of routine pretransplant screening are uncertain. Methods: We performed a systematic review and meta-analysis. Medical Literature Analysis and Retrieval System Online and Excerpta Medica database were searched to identify manuscripts published between 1998 and 2024 reporting the results of pretransplant screening. The primary end points were the frequency of detecting significant coronary lesions for which there are American Heart Association class 1 indications for revascularization: ( 1 ) >50% left main stenosis or ( 2 ) multivessel disease with ejection fraction <35% during prekidney transplant screening. Secondary end points included frequency of detecting multivessel disease, proximal left anterior descending artery disease, and number of patients who underwent invasive coronary angiography. Meta-regression was used to explore outcome heterogeneity according to the presence of hypertension, diabetes, and age. Results: We identified 1273 studies, out of which 44 met eligibility criteria. The mean prevalence of class 1 indications was 2%, although the heterogeneity was high with estimates ranging from 0% to 17%. Estimated prevalence of proximal left anterior descending disease was 2% and left main stenosis was 1%, whereas 10% of patients had multivessel coronary artery disease, and 35% were referred for invasive angiography. There was no evidence of significant heterogeneity according to sex of the population or prevalence of diabetes or hypertension. Conclusions: Identification of class 1 indications for revascularization during pretransplant coronary screening was rare. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_01_08_ASN0000000890.mp3
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 801-813
Class 1 Indications for Coronary Revascularization Identified in Prekidney Transplant Screening
Key Points: Coronary artery disease is a barrier to kidney transplantation. Many transplant programs mandate routine coronary artery disease screening. It remains unclear how many patients meet class 1 indication for revascularization. We conducted a meta-analysis to estimate the prevalence. Despite high frequency of screening, we found a relatively low prevalence of class 1 indication for coronary revascularization. Background: Cardiovascular disease is the most common cause of morbidity and mortality in kidney transplant recipients. Screening for coronary disease is frequently required before kidney transplantation, but coronary intervention has not been shown to be beneficial except in complex coronary artery disease. The likelihood of finding significant coronary artery disease and the benefits of routine pretransplant screening are uncertain. Methods: We performed a systematic review and meta-analysis. Medical Literature Analysis and Retrieval System Online and Excerpta Medica database were searched to identify manuscripts published between 1998 and 2024 reporting the results of pretransplant screening. The primary end points were the frequency of detecting significant coronary lesions for which there are American Heart Association class 1 indications for revascularization: ( 1 ) >50% left main stenosis or ( 2 ) multivessel disease with ejection fraction <35% during prekidney transplant screening. Secondary end points included frequency of detecting multivessel disease, proximal left anterior descending artery disease, and number of patients who underwent invasive coronary angiography. Meta-regression was used to explore outcome heterogeneity according to the presence of hypertension, diabetes, and age. Results: We identified 1273 studies, out of which 44 met eligibility criteria. The mean prevalence of class 1 indications was 2%, although the heterogeneity was high with estimates ranging from 0% to 17%. Estimated prevalence of proximal left anterior descending disease was 2% and left main stenosis was 1%, whereas 10% of patients had multivessel coronary artery disease, and 35% were referred for invasive angiography. There was no evidence of significant heterogeneity according to sex of the population or prevalence of diabetes or hypertension. Conclusions: Identification of class 1 indications for revascularization during pretransplant coronary screening was rare. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_01_08_ASN0000000890.mp3
- 5 November 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 23-30
Surrogate End Points in Apolipoprotein L1–Associated Kidney Disease
Key Points: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. Background: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 ( APOL1 )-associated kidney disease. Methods: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study ( N =3071), Chronic Renal Insufficiency Cohort ( N =998), and African American Study of Kidney Disease and Hypertension ( N =609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m 2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. Results: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. Conclusions: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 -associated kidney disease.
- 5 November 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 23-30
Surrogate End Points in Apolipoprotein L1–Associated Kidney Disease
Key Points: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. Background: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 ( APOL1 )-associated kidney disease. Methods: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study ( N =3071), Chronic Renal Insufficiency Cohort ( N =998), and African American Study of Kidney Disease and Hypertension ( N =609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m 2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. Results: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. Conclusions: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 -associated kidney disease.
- 1 August 2021
- Published by Oxford University Press (OUP)
- p. 39-54
Apathy in Alzheimer’s Disease
Apathy is characterized by diminished goal-directed activity, loss of emotion, and reduced engagement in social interactions. It is a common neuropsychiatric symptom in Alzheimer’s disease (AD) and is present throughout every stage of the disease. This chapter comprehensively discusses the prevalence of apathy, its impact on patient and caregiver outcomes, the diagnostic criteria and validated scales used in the assessment of apathy, the neurobiology of this neuropsychiatric symptom, and findings from studies investigating the treatment of apathy in AD. Recommendations for future research include validating apathy scales to identify and measure apathy in AD, and consideration of neuroimaging techniques and biomarker analyses to better predict treatment response.
- 1 August 2021
- Published by Oxford University Press (OUP)
- p. 39-54
Apathy in Alzheimer’s Disease
Apathy is characterized by diminished goal-directed activity, loss of emotion, and reduced engagement in social interactions. It is a common neuropsychiatric symptom in Alzheimer’s disease (AD) and is present throughout every stage of the disease. This chapter comprehensively discusses the prevalence of apathy, its impact on patient and caregiver outcomes, the diagnostic criteria and validated scales used in the assessment of apathy, the neurobiology of this neuropsychiatric symptom, and findings from studies investigating the treatment of apathy in AD. Recommendations for future research include validating apathy scales to identify and measure apathy in AD, and consideration of neuroimaging techniques and biomarker analyses to better predict treatment response.